Go Pro
→ The next convergence is here (From Digest Publishing) (Ad)tc pixel Free KALA Stock Alerts

KALA BIO (KALA) Competitors

KALA BIO logo
$0.56 +0.02 (+3.90%)
As of 09/21/2026 04:00 PM Eastern
Compare

KALA vs. ATNM, ATYR, CELU, CNTX, and MDXH

Should you buy KALA BIO stock or one of its competitors? KALA BIO's main competitors and comparable companies include Actinium Pharmaceuticals (ATNM), aTyr Pharma (ATYR), Celularity (CELU), Context Therapeutics (CNTX), and MDxHealth (MDXH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does KALA BIO compare to Actinium Pharmaceuticals?

Actinium Pharmaceuticals (NYSE:ATNM) and KALA BIO (NASDAQ:KALA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

Actinium Pharmaceuticals has a beta of 0.05, meaning that its stock price is 95% less volatile than the broader market. Comparatively, KALA BIO has a beta of -2.28, meaning that its stock price is 328% less volatile than the broader market.

Actinium Pharmaceuticals' return on equity of -100.85% beat KALA BIO's return on equity.

Company Net Margins Return on Equity Return on Assets
Actinium PharmaceuticalsN/A -100.85% -47.89%
KALA BIO N/A -222.35%-70.23%

In the previous week, Actinium Pharmaceuticals had 5 more articles in the media than KALA BIO. MarketBeat recorded 7 mentions for Actinium Pharmaceuticals and 2 mentions for KALA BIO. Actinium Pharmaceuticals' average media sentiment score of 1.08 beat KALA BIO's score of 0.00 indicating that Actinium Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Actinium Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
KALA BIO
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

27.5% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 24.6% of KALA BIO shares are held by institutional investors. 0.6% of Actinium Pharmaceuticals shares are held by company insiders. Comparatively, 2.2% of KALA BIO shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

KALA BIO has lower revenue, but higher earnings than Actinium Pharmaceuticals. KALA BIO is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Actinium Pharmaceuticals$35.09M1.08-$48.82M$0.363.33
KALA BION/AN/A-$26.98M-$31.96N/A

Actinium Pharmaceuticals presently has a consensus target price of $5.00, indicating a potential upside of 316.67%. KALA BIO has a consensus target price of $75.00, indicating a potential upside of 13,292.86%. Given KALA BIO's higher possible upside, analysts clearly believe KALA BIO is more favorable than Actinium Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Actinium Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
KALA BIO
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80

Summary

Actinium Pharmaceuticals beats KALA BIO on 10 of the 14 factors compared between the two stocks.

How does KALA BIO compare to aTyr Pharma?

aTyr Pharma (NASDAQ:ATYR) and KALA BIO (NASDAQ:KALA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

In the previous week, KALA BIO had 1 more articles in the media than aTyr Pharma. MarketBeat recorded 2 mentions for KALA BIO and 1 mentions for aTyr Pharma. aTyr Pharma's average media sentiment score of 0.00 equaled KALA BIO'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
aTyr Pharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
KALA BIO
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

aTyr Pharma's return on equity of -95.89% beat KALA BIO's return on equity.

Company Net Margins Return on Equity Return on Assets
aTyr PharmaN/A -95.89% -69.67%
KALA BIO N/A -222.35%-70.23%

aTyr Pharma has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market. Comparatively, KALA BIO has a beta of -2.28, indicating that its share price is 328% less volatile than the broader market.

KALA BIO has a consensus target price of $75.00, suggesting a potential upside of 13,292.86%. Given KALA BIO's higher probable upside, analysts clearly believe KALA BIO is more favorable than aTyr Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
aTyr Pharma
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.67
KALA BIO
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80

61.7% of aTyr Pharma shares are held by institutional investors. Comparatively, 24.6% of KALA BIO shares are held by institutional investors. 5.0% of aTyr Pharma shares are held by insiders. Comparatively, 2.2% of KALA BIO shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

KALA BIO has lower revenue, but higher earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
aTyr Pharma$190K192.46-$74.12M-$0.62N/A
KALA BION/AN/A-$26.98M-$31.96N/A

Summary

aTyr Pharma beats KALA BIO on 10 of the 14 factors compared between the two stocks.

How does KALA BIO compare to Celularity?

KALA BIO (NASDAQ:KALA) and Celularity (NASDAQ:CELU) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

KALA BIO has a beta of -2.28, meaning that its share price is 328% less volatile than the broader market. Comparatively, Celularity has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

24.6% of KALA BIO shares are owned by institutional investors. Comparatively, 19.0% of Celularity shares are owned by institutional investors. 2.2% of KALA BIO shares are owned by company insiders. Comparatively, 17.3% of Celularity shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, KALA BIO had 1 more articles in the media than Celularity. MarketBeat recorded 2 mentions for KALA BIO and 1 mentions for Celularity. KALA BIO's average media sentiment score of 0.00 equaled Celularity'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
KALA BIO
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Celularity
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

KALA BIO presently has a consensus price target of $75.00, indicating a potential upside of 13,292.86%. Given KALA BIO's stronger consensus rating and higher possible upside, equities research analysts plainly believe KALA BIO is more favorable than Celularity.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
KALA BIO
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80
Celularity
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

KALA BIO has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat KALA BIO's return on equity.

Company Net Margins Return on Equity Return on Assets
KALA BION/A -222.35% -70.23%
Celularity -345.45%N/A -77.94%

KALA BIO has higher earnings, but lower revenue than Celularity. Celularity is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
KALA BION/AN/A-$26.98M-$31.96N/A
Celularity$26.55M1.35-$91.72M-$3.33N/A

Summary

KALA BIO beats Celularity on 8 of the 13 factors compared between the two stocks.

How does KALA BIO compare to Context Therapeutics?

KALA BIO (NASDAQ:KALA) and Context Therapeutics (NASDAQ:CNTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

Context Therapeutics' return on equity of -82.06% beat KALA BIO's return on equity.

Company Net Margins Return on Equity Return on Assets
KALA BION/A -222.35% -70.23%
Context Therapeutics N/A -82.06%-72.74%

KALA BIO has a beta of -2.28, indicating that its stock price is 328% less volatile than the broader market. Comparatively, Context Therapeutics has a beta of 1.69, indicating that its stock price is 69% more volatile than the broader market.

KALA BIO presently has a consensus price target of $75.00, indicating a potential upside of 13,292.86%. Context Therapeutics has a consensus price target of $6.17, indicating a potential upside of 1,566.67%. Given KALA BIO's higher probable upside, equities research analysts plainly believe KALA BIO is more favorable than Context Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
KALA BIO
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80
Context Therapeutics
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.70

Context Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
KALA BION/AN/A-$26.98M-$31.96N/A
Context TherapeuticsN/AN/A-$36.12M-$0.48N/A

24.6% of KALA BIO shares are owned by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are owned by institutional investors. 2.2% of KALA BIO shares are owned by insiders. Comparatively, 4.8% of Context Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, KALA BIO had 1 more articles in the media than Context Therapeutics. MarketBeat recorded 2 mentions for KALA BIO and 1 mentions for Context Therapeutics. KALA BIO's average media sentiment score of 0.00 equaled Context Therapeutics'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
KALA BIO
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Context Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

KALA BIO and Context Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does KALA BIO compare to MDxHealth?

KALA BIO (NASDAQ:KALA) and MDxHealth (NASDAQ:MDXH) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

KALA BIO currently has a consensus target price of $75.00, suggesting a potential upside of 13,292.86%. MDxHealth has a consensus target price of $2.17, suggesting a potential upside of 261.11%. Given KALA BIO's higher probable upside, research analysts plainly believe KALA BIO is more favorable than MDxHealth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
KALA BIO
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80
MDxHealth
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

24.6% of KALA BIO shares are held by institutional investors. 2.2% of KALA BIO shares are held by insiders. Comparatively, 1.7% of MDxHealth shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, KALA BIO had 2 more articles in the media than MDxHealth. MarketBeat recorded 2 mentions for KALA BIO and 0 mentions for MDxHealth. KALA BIO's average media sentiment score of 0.00 equaled MDxHealth'saverage media sentiment score.

Company Overall Sentiment
KALA BIO Neutral
MDxHealth Neutral

KALA BIO has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. MDxHealth's return on equity of 0.00% beat KALA BIO's return on equity.

Company Net Margins Return on Equity Return on Assets
KALA BION/A -222.35% -70.23%
MDxHealth -33.46%N/A -24.25%

KALA BIO has a beta of -2.28, indicating that its share price is 328% less volatile than the broader market. Comparatively, MDxHealth has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market.

KALA BIO has higher earnings, but lower revenue than MDxHealth. MDxHealth is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
KALA BION/AN/A-$26.98M-$31.96N/A
MDxHealth$107.88M0.28-$33.52M-$0.72N/A

Summary

KALA BIO and MDxHealth tied by winning 7 of the 14 factors compared between the two stocks.

Get KALA BIO News Delivered to You Automatically

Sign up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KALA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KALA vs. The Competition

Export
MetricKALA BIOBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$10.42M$3.90B$7.26B$12.97B
Dividend YieldN/A3.64%2.53%12.80%
P/E Ratio-0.0214.12274.6925.77
Price / SalesN/A1,420.48696.46109.69
Price / CashN/A41.6228.0434.72
Price / Book0.0415.6010.566.36
Net Income-$26.98M-$22.86M$3.49B$358.17M
7 Day Performance10.30%0.81%0.81%1.60%
1 Month Performance-31.72%-4.59%-2.80%-2.97%
1 Year Performance-99.94%34.78%16.69%5.63%

KALA BIO Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KALA
KALA BIO
1.5242 of 5 stars		$0.56
+3.9%		$75.00
+13,292.9%		-99.9%$10.42MN/AN/A6
ATNM
Actinium Pharmaceuticals
2.7058 of 5 stars		$1.24
-0.8%		$5.00
+303.2%		-24.5%$38.99M$35.09MN/A30
ATYR
aTyr Pharma
0.6222 of 5 stars		$0.38
-1.3%		N/A-62.4%$38.18M$190KN/A53
CELU
Celularity
0.199 of 5 stars		$1.29
+4.0%		N/A-44.1%$35.89M$26.55MN/A220
CNTX
Context Therapeutics
2.4083 of 5 stars		$0.38
+4.0%		$6.17
+1,527.1%		-61.8%$33.48MN/AN/A7

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:KALA) was last updated on 9/22/2026 by MarketBeat.com Staff.
From Our Partners
MILLIONAIRE MASTERCLASS INVITE: Altucher
James Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altuche...
Paradigm Press | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
The next convergence is here
In 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel
Gold did this exact thing in 1975… [then exploded]
In 1975 the Fed raised rates and gold fell 50 percent. Headlines called the gold bull market dead. Instead gol...
Golden Portfolio | Sponsoredtc pixel
This free guide explains options the way they should be taught
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...
Base Camp Trading | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel
The AI Infrastructure Rush Is ON — Watch VDTA
Vertical Data Inc. (OTCQB: VDTA) is targeting the infrastructure layer beneath the AI boom, from GPU hardware ...
Trading Wire | Sponsoredtc pixel
Elon gets it. Do you?
Moderna's stock jumped nearly 200% in a single day after a successful Phase 3 trial for its cancer drug, and M...
Porter & Company | Sponsoredtc pixel